Efficacy of a Cryogenic Medical Device on Skin Tags Versus a Comparator Product.

Inclusion Criteria: * Healthy subject * Sex: male or female * Age: between 18 and 65 years old * Type: Caucasion * Phototype: I to III according to Fitzpatrick * Subject presenting at least one skin tag that could be treated by the tested devices on the neck, the breast, or under armpits of 2 to 5 mm diameter. * Subject having given freely and expressly his/her informed consent. * Subject who is able to comply with the study requirements, as defined in the present CIP, at the investigator's appreciation. * Subject being affiliated to a health social security system. * Female subjects of childbearing potential should use a medically accepted contraceptive regimen since at least 4 weeks before the beginning of the study and during all the study. Exclusion Criteria: * Pregnant, parturient, nursing woman or woman planning a pregnancy during the study. * Subject who had been deprived of their freedom by administrative or legal decision. * Subject who is under guardianship. * Subject having received 4500 euros indemnities for participation in clinical trials in the 12 previous months, including participation in the present study. * Subject currently participating in another research or being in an exclusion period for a previous study. * Subject suffering from an acute disease or any other pathology that may interfere with the evaluation of the study results at the investigator's opinion. * Subject with a cutaneous disease that may interfere with the evaluation of the study results or might put the subject at undue risk at the investigator's opinion. * Subject with a history of skin cancer. * Subject with a history of pre-cancerous skin lesions. * Subject with a known allergy to one of the component of the products, to the comparator, to nickel, to Biseptine® or any other Chlorhexidine based antiseptic or to the adhesive. * Subject suffering from asthma. * Subject who has diabetes. * Subject with previous event of healing disorders as hypertrophic or keloid scar, residual pigmentation etc. * Subject with blood circulation or blood clotting problems including Raynaud's disease; blood dyscrasias of unknown origin; haemophilia subjects. * Subject with immune deficiency or autoimmune disease. * Subject presenting birthmarks, moles, warts, or any other spots on the studied zone. * Subject having an inflamed, infected, irritated, red, damaged, cut, grazed, diseased or itchy skin on the treated zone. * Subject who already had an abnormal reaction to cold. * Subject whose selected skin tag is bleeding or scratched. * Subject undergoing a topical treatment on the test area or a systemic treatment: * anti-inflammatory medication during the previous 5 days and during the study, * immunosuppressors and/or corticoids during the 10 previous days and during the study, * retinoids during the 6 previous months and during the study, * treatment with an action on coagulation during the previous week and during the study, * any long-term medication stabilized for less than one month. * Subject who received a treatment of any type on the selected skin tag during the previous 6 months. * Intensive exposure to sunlight or UV-rays within the previous month and/or foreseen exposure of the treated zone during the study. * Subject planning to change her/his life habits during the study.